changing from semaglutide to zepbound Switching Tirzepatide Goodbye Compounded Semaglutide: GLP-1 Switch

Weight Loss with Semaglutide Average loss: 1416% of body weight Key trial: STEP 1 (New England Journal of Medicine) Population: Obese individuals without diabetes Notable: Significant appetite suppression and better cardiometabolic parameters reported by most participants Weight Loss with Tirzepatide Average loss: 21% or more of body weight at highest dose (15 mg) Key trial: SURMOUNT-1 Population: Obese and overweight adults without diabetes Remarkable: Highest rate of any FDA-approved weight loss medication to date Clinical Insight: Tirzepatide always beats Semaglutide in weight reduction

If your insurance doesnt cover the medication, it can be costly (medication + membership)

The majority of patients taking semaglutide do not experience dermatological reactions

Fortunately, several other strategies address the same underlying problems, including plateaus, side effects, and tolerance, without the complexity of medication cycling